Absci Corp ABSI
Institutional shares held
66.9 Million
361K
calls
542K
puts
Total value of holdings
$193M
$1.04M
calls
$1.56M
puts
Market Cap
$326M
92,843,504
Shares Out.
Institutional ownership
72.06%
# of Institutions
149
We take great care to ensure that the data presented and summarized in this overview for Absci Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ABSI
View all-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl11MShares$38.5 Million0.3% of portfolio
-
Redmile Group, LLC San Francisco, CA8.25MShares$29 Million2.18% of portfolio
-
Black Rock Inc. New York, NY5.34MShares$18.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.69MShares$16.5 Million0.0% of portfolio
-
Fred Alger Management, LLC New York, NY4.29MShares$15.1 Million0.07% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN2.59MShares$9.08 Million0.0% of portfolio
-
Massachusetts Financial Services CO Boston, MA2.31MShares$8.1 Million0.0% of portfolio
-
Ubs Group Ag2.06MShares$7.24 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2MShares$7.01 Million0.0% of portfolio
-
State Street Corp Boston, MA1.67MShares$5.86 Million0.0% of portfolio
Latest Institutional Activity in ABSI
Top Purchases
Top Sells
About ABSI
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
Insider Transactions at ABSI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 11
2025
|
Frans Van Houten Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,500
+38.34%
|
-
|
|
Jun 11
2025
|
Karen K Mcginnis Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,500
+27.45%
|
-
|
|
Jun 11
2025
|
Joseph Sirosh Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,500
+38.34%
|
-
|
|
Jun 11
2025
|
Daniel A Rabinovitsj Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,500
+38.34%
|
-
|
|
Jun 11
2025
|
Menelas N Pangalos Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,500
+44.38%
|
-
|
|
May 31
2025
|
Zachariah Jonasson CFO / CBO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,194
-1.23%
|
$10,388
$2.65 P/Share
|
|
Mar 03
2025
|
Andreas Busch Chief Innovation Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,700
+7.87%
|
-
|
|
Mar 03
2025
|
Sean Mc Clain Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
190,200
+2.22%
|
-
|
|
Mar 03
2025
|
Todd Bedrick SVP, CAO |
BUY
Grant, award, or other acquisition
|
Direct |
29,700
+15.04%
|
-
|
|
Mar 03
2025
|
Shelby J. Walker Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
59,300
+50.0%
|
-
|
|
Mar 03
2025
|
Zachariah Jonasson CFO / CBO |
BUY
Grant, award, or other acquisition
|
Direct |
81,500
+16.15%
|
-
|
|
Feb 28
2025
|
Zachariah Jonasson CFO / CBO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,219
-1.5%
|
$20,876
$4.04 P/Share
|
|
Feb 01
2025
|
Andreas Busch Chief Innovation Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,469
-0.58%
|
$4,407
$3.71 P/Share
|
|
Feb 01
2025
|
Todd Bedrick SVP, CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,630
-1.87%
|
$7,890
$3.71 P/Share
|
|
Feb 01
2025
|
Sean Mc Clain Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
16,991
-0.21%
|
$50,973
$3.71 P/Share
|
|
Feb 01
2025
|
Zachariah Jonasson CFO / CBO |
SELL
Payment of exercise price or tax liability
|
Direct |
11,567
-3.23%
|
$34,701
$3.71 P/Share
|
|
Nov 30
2024
|
Zachariah Jonasson CFO / CBO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,194
-1.43%
|
$15,582
$3.05 P/Share
|
|
Oct 12
2024
|
Andreas Busch Chief Innovation Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,092
-1.2%
|
$12,368
$4.07 P/Share
|
|
Oct 12
2024
|
Zachariah Jonasson CFO / CBO |
SELL
Payment of exercise price or tax liability
|
Direct |
242
-0.07%
|
$968
$4.07 P/Share
|
|
Oct 12
2024
|
Todd Bedrick SVP, CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
15,606
-10.09%
|
$62,424
$4.07 P/Share
|
Last 12 Months Summary
Buy / Acquisition
457K
Shares
From
10
Insiders
| Grant, award, or other acquisition | 457K shares |
|---|
Sell / Disposition
103K
Shares
From
4
Insiders
| Payment of exercise price or tax liability | 103K shares |
|---|